在阿尔茨海默氏病中微质纯能信号传递
Shu-Ya Mei1, Ning Zhang1, Meng-Jing Wang1
1School of Acupuncture and Tuina, Shaanxi University of Traditional Chinese Medicine, No. 1 Middle Section of Shi-Ji Avenue, Xianyang, Shaanxi, 712046, People's Republic of China.
Purinergic signalling
|June 23, 2024
概括
在阿尔茨海默病 (AD) 中的纯能信号传递涉及微质细胞. 特定的P2和腺受体可以恶化或保护AD病理,提供治疗点.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,其特征是粉样质斑块和神经纤维状结.
- 微质细胞,大脑的免疫细胞,是AD病变的核心,影响炎症和神经元功能.
- 纯能信号传递,涉及P2和腺素受体,在AD中关键调节微质活性.
研究的目的:
- 审查阿尔茨海默病,微质功能和纯能信号通路之间的复杂相互作用.
- 为了确定影响AD进展的微质上特定的纯能受体.
- 为了突出潜在的药理标在阿尔茨海默病治疗的纯能系统.
主要方法:
- 关于研究阿尔茨海默氏病中纯能信号的综合文献综述.
- 在AD的背景下分析微质纯敏受体表达 (P2X,P2Y,腺素A1/A2).
- 关于这些受体如何调节与AD相关的病理生理过程的综合证据.
主要成果:
- 微细胞表达离子型P2X4/P2X7和元型P2Y2/P2Y6/P2Y12/P2Y13受体,以及腺A1/A2A/A2B受体.
- 激活P2X4,P2X7和腺A1/A2A受体会加剧AD病理.
- 激活P2Y2,P2Y6,P2Y12,P2Y13和腺A1受体表明在AD中具有神经保护和抗炎作用.
结论:
- 纯能信号通路在阿尔茨海默病中起着双重作用,特定的受体介导有害或有益的影响.
- 向微质纯能受体提供了一个有前途的治疗策略来调节AD的发病性.
- 对这些受体的进一步研究可能会导致对阿尔茨海默病的新药理干预措施.
更多相关视频
相关概念视频
01:26Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462
01:22Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179